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Abstract
Background: Pilot trials are miniature researches carried out with the sole aim of acting as the precursor for larger
more definitive studies. Abstracts are used to summarize and introduce the findings to the reading audience. There
is substantive empirical evidence showing that abstracts, despite their important roles, are not informative enough,
lacking the necessary details. This systematic survey was designed to assess the quality of reporting of heart failure
pilot trial abstracts. The quality of reporting was defined as the completeness of reporting based on adherence to
the CONSORT extension for reporting of pilot trial abstracts. We also identified factors associated with
reporting quality.
Methods: We searched MEDLINE (PubMed), Cochrane Controlled Trials Register, Scopus, and African-wide
information databases for abstracts from heart failure pilot trials in humans published from 1 January 1990
to 30 November 2016. These were assessed to determine the extent of adherence to CONSORT extension
checklist for reporting of abstracts of pilot trials. We screened identified studies for inclusion based on title and
abstract. Data were independently extracted by two reviewers using the checklist. We used regression analysis to
assess the association between completeness of reporting (measured as the number of items in the CONSORT
extension checklist for reporting of abstracts in pilot trials contained in each abstract) and factors influencing the
quality of the reports.
Results: Two hundred and twenty-eight (228) articles were retrieved, of which 92 met the inclusion criteria. The
mean CONSORT extension score was 8.3/16 (standard deviation 1.7); the least reported items were the source of
funding (1% [1/92]), trial registration (13% [12/92]), randomization sequence (13% [12/92]), number randomized to
each arm (16% [15/92]), and number analyzed in each arm (16% [15/92]). Multivariable regression analysis showed
that pharmacological intervention pilot trials [incidence rate ratio (IRR) = 0.88; 95% confidence interval (CI), 0.81–0.97]
were significantly associated with better reporting. Other factors such as structured abstract (IRR = 1.10; 95% CI,
0.99–1.23) and CONSORT endorsement (IRR = 1.10; 95% CI, 0.99–1.23) only showed minimal relationship with better
reporting quality.
Conclusion: The quality of reporting of abstracts of heart failure pilot trials was suboptimal. Pharmacological
intervention was significantly associated with better reporting. These findings are consistent with previous
research on reporting of trials.
* Correspondence: thabanl@mcmaster.ca
4Department of Health Research Methods, Evidence, and Impact, McMaster
University, Hamilton, ON, Canada
5Biostatistics Unit/FSORC, Father Sean O’Sullivan Research Centre, St Joseph’s
Healthcare-Hamilton, 50 Charlton Avenue East, 3rd Floor Martha Wing, Room
H325, Hamilton, ON L8N 4A6, Canada
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Isiguzo et al. Pilot and Feasibility Studies  (2018) 4:107 
https://doi.org/10.1186/s40814-018-0302-8
Background
Numerous challenges confront readers while accessing
the literature; these include but are not limited to the
enormous volume of published work, the high cost of
obtaining articles especially in resource-limited settings
[1], and language constraints when articles are not writ-
ten in users’ language [2]. The outcome of this has been
an over-reliance on abstracts for articles as a one-stop
point for most researchers. Abstracts of journal articles
or scientific papers often provide readers with an over-
view of the content of the full article. As a result,
researchers tend to rely on abstracts as a concise source
of information [3] and in making decisions on which
publications to read in detail [4]. Furthermore,
researchers rely largely on the abstract when deciding
whether to include an article in a systematic review [5].
All these factors make the abstract a key section of the
scientific publication. It is, therefore, important that
abstracts of articles are consistent with what is reported
in the text and capture essential information.
Randomized control trials (RCT) constitute a signifi-
cant portion of clinical studies and most times are the
core component for systematic reviews. However, the
quality of reporting of RCTs have over the years
attracted many questions, mostly related to consistency
and completeness of reports [6]. The Consolidated
Standard for Reporting of Trials (CONSORT) checklist
was conceptualized in 1996 to address these issues. Its
publication and instant acceptance led to revisions in
2007 and 2010 [7, 8]. Many journals have adopted the
CONSORT checklist, and it has been shown to improve
the quality of reporting RCTs [9–11].
The overwhelming acceptance of CONSORT checklist
has led to the development of extensions to incorporate
other types of RCTs. Due to the need to widen the scope
of the checklist, in 2016, the CONSORT extension
checklist for abstracts of pilot trials was developed to aid
adequate reporting of pilot trials [12], an important but
often neglected arm of medical research [13].
We conducted this systematic survey to evaluate the
quality of reporting of abstracts of pilot RCTs in heart
failure published 1990–2016. Heart failure, defined as a
clinical condition in which the heart does not pump
blood sufficiently or does so at a higher pressure to
maintain the body’s need [14, 15], has been a prominent
cause of cardiovascular disease burden in Africa in the
last two decades [16, 17]. It has also attracted many clin-
ical trials in the last two decades (1990–2016), most of
which were preceded by pilot trials [17]. The quality
reporting is defined as complete reporting of the 16
items in the CONSORT extension checklist.
The aims of this survey are to (1) evaluate the quality
of reporting of abstracts of pilot RCTs in the past
26 years (1990–2016), using the CONSORT extension
for reporting of abstracts of pilot trials; (2) identify
aspects of the checklist that are consistently reported;
(3) identify factors associated with better reporting of
abstracts; and (4) determine the quality (completeness)
of abstracts of pilot trials.
Methods
Randomized controlled pilot trials in heart failure published
from 1 January 1990 to 30 November 2016 were searched
for in line with the systematic survey method as previously
described [17]. Abstracts were selected if they were de-
scribed as random, randomly allocated, and randomized.
We searched the MEDLINE (PubMed), Cochrane Con-
trolled Trials Register, Scopus, and African-wide informa-
tion databases (search strategy in the Additional file 1). We
limited our search to pilot trial reports written in English
language only. Two reviewers independently screened the
identified papers and those finally selected to assess the
quality of reporting of abstracts using the 16 items of
CONSORT extension for reporting of abstract of pilot tri-
als. We assigned a score of one to an item on the CON-
SORT checklist if the item was reported in the abstract.
The overall quality of abstract was calculated as the propor-
tion of “yes” responses. We classified abstracts that re-
ported all the 16 items in the CONSORT checklist as
adequate quality reporting.
We hypothesized that pilot trials published in high impact
journals [18], published in CONSORT-endorsing journals
[19, 20], those on pharmacological interventions [20], stud-
ies with large sample sizes [21], and industry-funded studies
[22] would have better reporting quality.
The protocol for this systematic survey [17] was regis-
tered with PROSPERO (CRD42016049911) and written
according to the Preferred Reporting Items for System-
atic Reviews and Meta-Analysis Extension for Protocols
(PRISMA-P) [23].
Statistical analysis
The analysis was with IBM statistical package for social
sciences (IBM SPSS) version 24 (IBM Corp., Armonk,
NY) and STATA 9.0 (College Station, TX). We calculated
the percentage of trials that scored yes on each of the 16
items and the associated 95% confidence interval (CI).
We reported categorical variables as count and per-
centages; continuous variables are summarized as mean
(standard deviation (SD)) or median (interquartile range
(IQR)). Incidence risk ratio (IRR) was calculated to iden-
tify factors associated with better reporting. Negative
binomial regression was conducted to determine factors
associated with better reporting quality.
Results
Our search identified 228 articles; after the screening,
one hundred and thirty-six articles were found to be
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ineligible based on several reasons (Fig. 1). A total of 92
articles from 48 journals were eligible; among these, 12
were conference presentations. The three highest
contributing journals were European Journal of Heart
Failure (9 articles; 9.8%), American Heart Journal (8 ar-
ticles; (8.7%), Journal of American College of Cardiology
(7 articles; 7.6%), and Journal of Cardiac Failure (7 arti-
cles; 7.6%).
Study characteristics
The estimate of Kappa statistic for inter-rater agreement
for screening publications for eligibility was 0.82 [95%
confidence interval (CI), 0.76–0.87]. A majority (71%) of
the studies were published between 2001 and 2016
(Table 1). Both pharmacological intervention studies and
non-pharmacological intervention studies were 45 (49%),
respectively; two studies (2%) had both pharmacological
and non-pharmacological interventions. The abstract
presentation was structured in 80% of the studies. In 62
of 92 (67%) of the studies, the CONSORT statement was
not endorsed by the publisher. Most (74%) of the studies
were conducted at a single site.
Quality of reporting of abstracts of pilot trials
None of the studies reported all the 16 items in the check-
list (Table 2), the maximum reported number of items was
12, with a mean (SD) of 8.3 (1.7) items. The most reported
item was the type of intervention intended for each group
Fig. 1 Study flow
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99% (95% CI 91; 99), followed by specified objectives of the
pilot trial 94% (95% CI 89; 99) and pre-specified outcome
to address pilot trial objectives 97% (95% CI 90; 98).
The least reported item was funding source 1%
(95% CI 0.16; 6.9); however, 21 of 92 (22.8%) studies re-
ported funding source in the main manuscript but not in
the abstract. Inadequately reported items include the
randomization method used 13% (95% CI 8; 19), trial regis-
tration information 13% (95% CI 7; 21), and the number of
participants screened in each arm 16% (95% CI 9; 26).
Recruitment status, an item in the CONSORT checklist
that addresses conference presentation, was low with 2%
(95% CI 5; 8) among the 12 conference abstracts.
Multivariable analysis (Table 3) of factors associated
with reporting quality showed pharmacological interven-
tion is significantly associated with better reporting qual-
ity (IRR 0.88; 95% CI 0.81; 0.97; p value 0.01), while
structured abstract (IRR 1.10; 95% CI 0.99; 1.23; p value
0.05) did not have a strong association. Journals
which endorsed CONSORT was not a significant
factor (IRR 1.10; 95% CI 0.99; 1.23; p value 0.06).
Discussion and conclusions
The CONSORT extension for reporting of abstracts of
pilot trials was introduced in 2016 to standardize the
reporting of abstracts of such studies. We undertook this
Table 1 Characteristics of included papers: n = 92
Characteristic Count (%)/median (Q1; Q3)
Year of publication
1990–2006 26 (28%)
2007–2016 66 (72%)
Intervention type (n = 90)
Pharmacological 45 (49%)
Non-pharmacological 45 (49%)
Both pharmacological and
non-pharmacological
2 (2%)
Abstract format
• Structured 74/92 (80%)
• Unstructured 18/92 (20%)
CONSORT endorsement
• Yes 30/92 (33%)
• No 62/92 (67%)
Number of sites
• Single 61/82 (74%)
• Multiple 21/82 (26%)
Study duration in months (n = 68) 3.0 (2.6; 6.1)
Sample size (n = 88) 41 (24; 88)
CONSORT Consolidated Standards of Reporting Trials, Q1 first quartile, Q3
third quartile
Table 2 Publication adherence to CONSORT checklist for abstract of pilot trials n = 92
Item Criteria Count Percent (95% CI)
Title Identifier Title identifies the study is a randomized controlled pilot trial 65 71 (60; 79)
Description Trial design Description of pilot trial design (e.g., parallel or cluster) 30 33 (23; 44)
Method Eligibility Eligibility criteria for each participant 81 88 (78; 94)
Settings Setting where pilot was conducted 29 32 (22; 47)
Interventions Interventions intended for each group 91 99 (91; 99)
Objectives Specific objectives of the pilot trial 89 94 (89; 99)
Outcomes Pre-specified assessment or measurement to address the
pilot trial objectives
89 97 (90; 98)
Randomization sequence
generation
Describe how participants were allocated to the interventions 12 13 (8; 19)
Blinding (masking) Whether or not participants, caregivers, and those assessing
the outcomes were blinded to group assignment
20 22 (15; 31)
Results Number randomized Number of participants screened 15 16 (9; 26)
Number randomized to each group for the pilot objectives 41 45 (36; 53)
Recruitment Trial status (for conference abstracts) 2 2 (5; 8)
Numbers analyzed Number of participants analyzed in each group of pilot objectives 15 16 (11; 24)
Harm Important adverse events or side effects 28 30 (23; 39)
Conclusion Result interpretation General interpretation of results of pilot trial 80 87(76; 93)
Plans Any implication for future trial 20 22 (15; 30)
Registration Trial registration Registration number of trial 12 13 (7; 21)
Funding Source of funding 1 1 (0.16; 6.9)
CI confidence interval
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survey to gauge the current practice using heart failure
pilot trials as a sample to track reporting quality
improvement expected with introduction and adherence
to the extension. We found inadequate reporting quality
in keeping with previous articles evaluating adherence to
CONSORT checklist on abstracts [8, 24, 25].
The least reported item was the funding source, simi-
lar to findings in a previous study [26]. The full declar-
ation of funding source in a publication can give the
reader the opportunity to make their own assessment
regarding potential conflict of interest. However, we
noticed that 22/96 of the articles had information on
funding in other places rather than the abstract, and this
may not be unrelated to word count stipulation by indi-
vidual journals. Often, this poses a challenge to authors
on what to include in abstracts, and there may be the
need for CONSORT extension checklist developers to
consider this limitation.
The randomization sequence was also poorly re-
ported. It is an item that can provide acceptable com-
parability between groups if properly reported. Some
previous studies have commented on this methodo-
logical flaw [10, 27–29], explaining that this could be
because of attachment of more relevance to clinical
than the methodological aspect of RCTs. There has
been corroborating evidence in other studies support-
ing a correlation between deficient reporting and poor
trial methodology [30–32].
Many of the articles were also silent on the blinding,
and when used, some failed to state the group blinded in
the studies. Not being explicit about blinding erodes the
integrity and internal validity of the reports, and it is a
potential source of bias among the readers [33, 34].
Reporting on harm was low at 28%; this is an essential
item as it informs the design and applicability of
intended larger trials. Previously, this safety reporting
has often been inadequate or neglected [35]. And, in
literature, there is highly variable adherence to reporting
of harm [36, 37].
Methodological aspects reported include intervention
type, specific objective, and outcomes to be assessed.
Many of the articles identified them as pilot trials; this
was despite the constraint of word limit by journals, a
reason often adduced as responsible for not including
this [10, 26, 29]. Also, pilot trials with pharmacological
intervention, those with structured abstracts, and those
published in the journal that endorses CONSORT were
more likely to report on the items on the checklist. The
last point brings to fore why it is important for journals
to have stipulated reporting format to ensure that the
quality of abstracts’ report is improved.
Our study is limited in scope by using only articles
published in the English language. We also used a re-
cently produced checklist to evaluate publications done
by authors who at the time of writing of the articles
probably had no reporting checklist to follow.
In conclusion, the reporting quality of abstracts of
heart failure trial measured by the number of items
reported was suboptimal; the need to guard against this
was the reason that informed the introduction of CON-
SORT extension checklist. The desire is that increasingly
journals will demand adherence to the checklist by
authors. Ultimately, we hope that there will be a marked
improvement in the quality of report of abstracts in the
coming years.
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